Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

The Lancet Oncology

Volumn 17, Issue 6, 2016, Pages 717-726

  Muro, Kei ^a   Chung, Hyun Cheol ^b   Shankaran, Veena ^c   Geva, Ravit ^d   Catenacci, Daniel ^e   Gupta, Shilpa ^f   Eder, Joseph Paul ^g   Golan, Talia ^h   Le, Dung T ⁱ   Burtness, Barbara ^j   McRee, Autumn J ^k   Lin, Chia Chi ^l   Pathiraja, Kumudu ^m   Lunceford, Jared ^m   Emancipator, Kenneth ^m   Juco, Jonathan ^m   Koshiji, Minori ^m   Bang, Yung Jue ⁿ  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b Yonsei University College of Medicine   (South Korea)

^c UNIVERSITY OF WASHINGTON   (United States)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g YALE UNIVERSITY   (United States)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j FOX CHASE CANCER CENTER   (United States)

^k UNIVERSITY OF NORTH CAROLINA   (United States)

^l NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^m MERCK RESEARCH LABORATORIES   (United States)

ⁿ Seoul National University College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CANCER FATIGUE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DECREASED APPETITE; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HYPOTHYROIDISM; INTERSTITIAL LUNG DISEASE; LARYNX DISORDER; MALE; METASTASIS; METASTASIS POTENTIAL; MULTICENTER STUDY; PEMPHIGOID; PERIPHERAL SENSORY NEUROPATHY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PRURITUS; SENSORY NEUROPATHY; STOMACH ADENOCARCINOMA; STOMACH CANCER; TREATMENT DURATION; ADENOCARCINOMA; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECONDARY; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84964779633     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)00175-3     Document Type: Article

References (31)

1. 1 Ferlay, J, Soerjomataram, I, Dikshit, R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. 2 Catalano, V, Labianca, R, Beretta, GD, et al. Gastric cancer. Crit Rev Oncol Hematol 71 (2009), 127–164.
3. 3 Bang, YJ, Van Cutsem, E, Feyereislova, A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376 (2010), 687–697.
4. 4 Fuchs, CS, Tomasek, J, Yong, CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 (2014), 31–39.
5. 5 Wilke, H, Muro, K, Van Cutsem, E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15 (2014), 1224–1235.
6. 6 Keir, ME, Butte, MJ, Freeman, GJ, Sharpe, AH, PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 (2008), 677–704.
7. 7 Pardoll, DM, The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
8. 8 Topalian, SL, Drake, CG, Pardoll, DM, Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24 (2012), 207–212.
9. 9 Sun, J, Xu, K, Wu, C, et al. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens 69 (2007), 19–27.
10. 10 Kim, JW, Nam, KH, Ahn, SH, et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer 19 (2016), 42–52.
11. 11 Qing, Y, Li, Q, Ren, T, et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther 9 (2015), 901–909.
12. 12 Taube, JM, Anders, RA, Young, GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med, 4, 2012, 127ra37.
13. 13 Merck & Co. Keytruda® (pembrolizumab) injection, for intravenous use, 2015, Merck & Co, Whitehouse Station.
14. 14 Patnaik, A, Kang, SP, Rasco, D, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 21 (2015), 4286–4293.
15. 15 Merck & Co. FDA approves Keytruda® (pembrolizumab) for the treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 with disease progression on or after platinum-containing chemotherapy. http://www.mercknewsroom.com/news-release/prescription-medicine-news/fda-approves-keytruda-pembrolizumab-treatment-patients-metas, Oct 2, 2015 (accessed April 22, 2016).
16. 16 Das, S, Suarez, G, Beswick, EJ, et al. Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J Immunol 176 (2006), 3000–3009.
17. 17 Wu, C, Zhu, Y, Jiang, J, et al. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108 (2006), 19–24.
18. 18 Hou, J, Yu, Z, Xiang, R, et al. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp Mol Pathol 96 (2014), 284–291.
19. 19 Geng, Y, Wang, H, Lu, C, et al. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int J Clin Oncol 20 (2015), 273–281.
20. 20 Dolled-Filhart, M, Locke, D, Murphy, T, et al. Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue. Arch Pathol Lab Med, 2016 in press.
21. 21 Dako North America. PD-L1 IHC 22C3 pharmDx interpretation manual. http://www.dako.com/us/29109_pd-l1-ihc-22c3-interpretation-manual.pdf (accessed April 22, 2016).
22. 22 Bellmunt, J, Mullane, SA, Werner, L, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol 26 (2015), 812–817.
23. 23 Ribas, A, Robert, C, Hodi, S, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. Proc Am Soc Clin Oncol, 33(suppl), 2015 abstract 3001.
24. 24 Robert, C, Ribas, A, Wolchok, JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384 (2014), 1109–1117.
25. 25 Robert, C, Schachter, J, Long, GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
26. 26 Ribas, A, Puzanov, I, Dummer, R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16 (2015), 908–918.
27. 27 Garon, EB, Rizvi, NA, Hui, R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
28. 28 Pasechnikov, V, Chukov, S, Fedorov, E, Kikuste, I, Leja, M, Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol 20 (2014), 13842–13862.
29. 29 Elimova, E, Shiozaki, H, Wadhwa, R, et al. Medical management of gastric cancer: a 2014 update. World J Gastroenterol 20 (2014), 13637–13647.
30. 30 Cancer Genome Atlas Network, Cancer Genome. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513 (2014), 202–209.
31. 31 Stahl, P, Seeschaaf, C, Lebok, P, et al. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol, 15, 2015, 7.